Literature DB >> 8585045

Central retinal vein and branch artery occlusion associated with inherited plasminogen deficiency and high lipoprotein(a) levels: a case report.

A Tavola1, S V D'Angelo, F Bandello, R Brancato, M Parlavecchia, O Safa, A D'Angelo.   

Abstract

We describe a case of central retinal vein and branch artery occlusion associated with inherited type I plasminogen deficiency (68%) and permanent elevation of Lp(a) (460 mg/l, S2 phenotype) in a 45 year old white woman with no associated local or systemic risk factors. Pedigree analysis revealed inheritance of plasminogen deficiency from the deceased father and of high Lp(a) levels from the mother. Both the patient's sons had plasminogen deficiency, but they had normal Lp(a) levels. In a series of 40 consecutive patients with central retinal vein occlusion we previously reported the observation of high Lp(a) levels--consistently associated with the S2 phenotype--in 30% of the patients as compared to a 10% incidence in controls. This case emphasizes the importance of screening patients with occlusion of the retinal vessels and no associated risk factors for coagulation abnormalities predisposing to thrombosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8585045     DOI: 10.1016/0049-3848(95)00183-r

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  3 in total

1.  Concurrent branch retinal artery occlusion in central retinal vein occlusion: 3 cases reports and literature review.

Authors:  Neha Goel
Journal:  Saudi J Ophthalmol       Date:  2021-02-27

2.  Homocysteine, MTHFR C677T gene polymorphism, folic acid and vitamin B 12 in patients with retinal vein occlusion.

Authors:  Paola Ferrazzi; Pierpaolo Di Micco; Ilaria Quaglia; Lisa Simona Rossi; Alessandro Giacco Bellatorre; Giorgio Gaspari; Lidia Luciana Rota; Corrado Lodigiani
Journal:  Thromb J       Date:  2005-09-07

3.  Comorbidities in combined retinal artery and vein occlusions.

Authors:  Dieter Schmidt
Journal:  Eur J Med Res       Date:  2013-08-16       Impact factor: 2.175

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.